The interferons (IFNs) are glycoproteins which have, in addition to anti-viral activity, antiproliferative and immunomodulating properties (Borden, 1979; Billiau, 1981) . The latter two suggested an anti-tumour potential for these substances and IFN has now been used in the treatment of a variety of malignant diseases. To date, there have been no reports of its use in human hepatocellular carcinoma (HCC). There is considerable epidemiological, serological and molecular biological evidence implicating the hepatitis-B virus in the aetiology of HCC (Kew, 1981) , and this provides an additional reason for investigating the effects of IFN on the course of this tumour. We report a pilot trial of recombinant leucocyte alpha IFN (IFLrA; Hoffman la Roche) in the treatment of HCC.
Sixteen patients with inoperable HCC were entered in the trial (Table I) . With one exception, all were histologically proved. The exception (no. 16) was considered to have HCC on the basis of the clinical findings and a serum alpha-foetoprotein (AFP) concentration of 8 x 103 ng ml -(normal <10). Five patients had a well-differentiated, 8 a moderately-differentiated, and 2 a poorlydifferentiated tumour. A trabecular pattern was present in 9 patients, a solid pattern in 3 and a scirrhous pattern in 3. One patient had a clear cell variant. The disease was confined to the liver in 13 patients and 3 had pulmonary metastases. All the patients conformed to required inclusion criteria with respect to haematological function (haemoglobin > 10gdl-1, leucocyte count >3 x 1091-1 granulocytes > 1091-1, platelets > 30 x 1091-1) and renal function (blood urea and creatinine levels < 2.5 times upper limit of normal). Although hepatic function tests were abnormal, impairment was not severe enough to exclude these patients from the trial (prothrombin ratio > 2.5 times normal was considered to indicate severe hepatic impairment). A complete remission was defined as disappearance of all evidence of tumour; regression as a definite decrease in tumour size determined by two investigators; stable disease as no definite increase or decrease in tumour size assessed by two investigators; and progression as a definite increase in tumour size or the appearance of a new lesion agreed by two investigators.
Only 2 patients (nos. 5, 9) completed the 12 week course of treatment (Table II) . In patient no. 5 the disease remained stable during this period, and she has since received 4 further courses of IFLrA at the same (low) dosage. The disease was slowly progressive for 1 year after therapy was initiated but in the past few months her condition has deteriorated markedly and she has become deeply jaundiced. Patient no. 9 showed progressive disease, (Desmyter et al., 1981) . Neither human leucocyte or fibroblast IFN exhibited a tumourinhibitory effect in nude mice injected with PLC/PRF/5 cells (Desmyter et al., 1981) . In another study, anti-IFN antibody enhanced tumour growth and invasiveness of PLC/PRF/5 cells (Shouval et al., 1983) .
Our trial showed little efficacy of IFLrA in 16 black patients with advanced HCC. Only 2 patients completed the 12-week treatment period, one with slowly progressive and the other with obviously progressive disease. The former may have a less fulminant, slower-growing type of HCC similar to that observed in western patients and occasionally encountered in black patients. The possibility exists that indolent tumours may respond better to IFN than aggressive malignancies. Of the remaining 14 patients, 13 showed rapidly progressive disease culminating in death. Death was considered to be the result of tumour progression alone in 6 patients, and of combined tumour progression and drug toxicity in 5 patients. Drug-related side effects necessitated discontinuation of treatment in 3 patients, 2 of whom subsequently died of their disease, and one patient was lost to follow-up.
Although the majority of the patients were of high performance status when they entered the trial, many of them deteriorated rapidly on therapy and 9 of the 16 received less than 4 weeks of treatment. These patients clearly had advanced and rapidly progressive disease and this raises the issue of whether patients of this sort are suitable for a phase II trial.
Numerous side effects have been described with leucocyte IFN-ax, and they were frequently encountered in the present study. One possible reason for this may be elevated blood levels of the drug consequent upon hepatic dysfunction, since IFN is possibly metabolised in the liver (Desmyter et al., 1981; Bocci, 1981) . The possibility that hepatic encephalopathy was precipitated by IFN needs to be considered in relation to the neurological side effects. However, liver function was usually good and none of the patients showed obvious signs of hepatic pre-coma.
In conclusion, the results obtained in this pilot trial of IFLrA were as disappointing as those which have been achieved with other forms of cancer chemotherapy in black patients with HCC. This is not altogether unexpected as the tumours were large and it is known that large tumours respond poorly to IFN. We encountered significant drug tocixity in these patients and this was not restricted to the patients receiving the higher doses.
Nevertheless, IFN may possibly have a part to play in the treatment of less advanced HCC or as an adjuvant to other modes of treatment.
